STAT+: Gene therapy’s long-debated cancer risk materializes
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The tumors possibly connected to pediatric gene therapies make me sad. Babies. The need-to-know this morning Vir Biotechnology said monthly injections of two experimental medicines reduced hepatitis D virus to undetectable levels in 44% of patients compared to none of the patients who received delayed treatment with the same regimen. The result achieved the primary goal of...
Read full article →